Learn More
Despite 'orphan drug' legislation, bringing new medicines for rare diseases to market and securing funding for their provision is sometimes both costly and problematic, even in the case of medicines for very rare 'ultra orphan' oncological indications. In this paper difficulties surrounding the introduction of a new treatment for osteosarcoma exemplify the(More)
(2001) Setting Up Collaborative Partnership Research in FE: When the " Big One " meets " a world of rabbit warrens ". Users may access full items free of charge; copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational or not­for­profit(More)
Sir, We note Professor Bielack's concern (Bielack, 2012) regarding our reference to his European Journal of Cancer Care editorial 'Osteosarcoma: time to move on?' (Bielack, 2010). However, he misinterprets the reason for our reference to his contribution. We were not suggesting that Professor Bielack had said that he had fears that 'the viability of the(More)